This is a summary of the European public assessment report (EPAR) for Adasuve. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adasuve.
Therapeutic Indication
### Therapeutic indication Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Therapeutic Area (MeSH)
N/AATC Code
N05AH01
ATC Item
loxapine
Pharmacotherapeutic Group
Nervous system
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| loxapine | N/A | 洛沙平 |
EMA Name
Adasuve
Medicine Name
Adasuve
Aliases
N/ANo risk management plan link.
